Richard Torstenson
BioPharmaceuticals R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Journal: Journal of hepatology
Published: September 30, 2022
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Journal: The lancet. Gastroenterology & hepatology
Published: September 21, 2022
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Journal: Hepatology (Baltimore, Md.)
Published: June 16, 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
Journal: Journal of clinical and translational hepatology
Published: September 12, 2021
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Journal: Journal of hepatology
Published: May 12, 2021
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
Journal: Contemporary clinical trials
Published: May 25, 2020
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
Journal: Gastroenterology
Published: April 15, 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
Journal: Hepatology (Baltimore, Md.)
Published: July 21, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026